On the public citation graph

Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer

https://doi.org/10.1038/bjc.2017.95
0 signed · 78 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2016.4324openalex-snapshot
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib
inferredcites →https://doi.org/10.1002/cncr.28382openalex-snapshot
A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites
inferredcites →https://doi.org/10.1016/j.ijrobp.2015.08.026openalex-snapshot
Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer
inferredcites →https://doi.org/10.1016/j.radonc.2015.08.026openalex-snapshot
Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP trial
inferredcites →https://doi.org/10.1016/j.radonc.2016.03.021openalex-snapshot
ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer
inferredcites →https://doi.org/10.1016/j.radonc.2016.07.002openalex-snapshot
Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: Analysis of the on-trial cases for the SCALOP trial
inferredcites →https://doi.org/10.1016/j.surg.2011.07.006openalex-snapshot
Neoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trials
inferredcites →https://doi.org/10.1016/s1470-2045(13)70021-4openalex-snapshot
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial
inferredcites →https://doi.org/10.1200/jco.2006.07.5663openalex-snapshot
Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4706360openalex-extracted
Standard or High Dose Chemoradiotherapy, with or Without the Protease Inhibitor Nelfinavir, for the Treatment of Locally Advanced Pancreatic Cancer: Efficacy, Safety and Health-Related Quality of Life Outcomes from the Multi-Centre Two Stage Phase 1/Randomised Phase 2 SCALOP-2 Study
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.48147openalex-snapshot
Survival After Minimally Invasive vs Open Surgery for Pancreatic Adenocarcinoma
inferred← citeshttps://doi.org/10.1002/14651858.cd011044.pub3openalex-snapshot
Chemotherapy and radiotherapy for advanced pancreatic cancer
inferred← citeshttps://doi.org/10.1002/cam4.5523openalex-snapshot
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline‐resectable and locally‐advanced pancreatic cancer patients
inferred← citeshttps://doi.org/10.1002/cam4.6100openalex-snapshot
Treatment patterns and cost estimations of systemic chemotherapy for pancreatic cancer in Japan: A retrospective database study
inferred← citeshttps://doi.org/10.1002/cam4.70648openalex-snapshot
Multi‐Institutional Phase II Study on the Efficacy and Safety of Dynamic Tumor‐Tracking, Moderately Hypofractionated Intensity‐Modulated Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
inferred← citeshttps://doi.org/10.1002/cncr.35936openalex-snapshot
A phase 1 dual‐dose escalation study of radiation and nab‐paclitaxel in patients with unresectable and borderline resectable pancreatic cancer
inferred← citeshttps://doi.org/10.1002/cnr2.70531openalex-snapshot
Effect of First‐Line Chemotherapy Alone Versus First‐Line Chemotherapy Plus Radiotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer in the IMRT Era: A Retrospective Cohort Study
inferred← citeshttps://doi.org/10.1002/jso.27773openalex-snapshot
Understanding futility in pancreaticoduodenectomy: Insights from a national cohort
inferred← citeshttps://doi.org/10.1002/mco2.70117openalex-snapshot
Endoscopic Ultrasound‐Guided Brachytherapy of Yttrium‐90 Implantation Into Pancreas: A Dose‐Escalation Pilot Study
inferred← citeshttps://doi.org/10.1002/mco2.70162openalex-snapshot
Pancreatic Cancer: Pathogenesis and Clinical Studies
inferred← citeshttps://doi.org/10.1002/pro6.1080openalex-snapshot
Changing paradigm of radiation therapy for the treatment of pancreatic cancer
inferred← citeshttps://doi.org/10.1002/prp2.898openalex-snapshot
Analysis of capecitabine metabolites in conjunction with digital autoradiography in a murine model of pancreatic cancer suggests extensive drug penetration through the tumor
inferred← citeshttps://doi.org/10.1007/978-3-319-98944-0_11openalex-snapshot
Role of Radiation for Locally Advanced Pancreatic Cancer
inferred← citeshttps://doi.org/10.1007/s00432-018-2666-9openalex-snapshot
Emerging strategies in BRCA-positive pancreatic cancer
inferred← citeshttps://doi.org/10.1007/s00595-020-02123-2openalex-snapshot
FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience
inferred← citeshttps://doi.org/10.1007/s00740-020-00326-4openalex-snapshot
Rolle der Radiotherapie beim Pankreaskarzinom
inferred← citeshttps://doi.org/10.1007/s00761-019-0546-9openalex-snapshot
Rolle der Radiotherapie beim Pankreaskarzinom
inferred← citeshttps://doi.org/10.1016/b978-0-323-91689-9.00016-9openalex-snapshot
Pancreatic cancers
inferred← citeshttps://doi.org/10.1016/b978-0-443-19142-8.00008-5openalex-snapshot
Clinical practice guidelines for interventional treatment of pancreatic cancer
inferred← citeshttps://doi.org/10.1016/j.adro.2025.101742openalex-snapshot
Long-Term Survival Following Chemoradiation in Locoregional Recurrent Germline ATM Mutated Pancreatic Ductal Adenocarcinoma
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2023.104013openalex-snapshot
Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: Current evidence and new perspectives
inferred← citeshttps://doi.org/10.1016/j.currproblcancer.2017.10.006openalex-snapshot
Locally advanced pancreatic cancer: An emerging entity
inferred← citeshttps://doi.org/10.1016/j.ejca.2024.114236openalex-snapshot
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial
inferred← citeshttps://doi.org/10.1016/j.ejso.2018.07.047openalex-snapshot
Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment?
inferred← citeshttps://doi.org/10.1016/j.esmoop.2022.100552openalex-snapshot
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)
inferred← citeshttps://doi.org/10.1016/j.jimed.2022.10.001openalex-snapshot
Irreversible electroporation of the pancreas – A decade on
inferred← citeshttps://doi.org/10.1016/j.jss.2025.03.047openalex-snapshot
Machine Learning to Predict Early Death Despite Pancreaticoduodenectomy
inferred← citeshttps://doi.org/10.1016/j.radonc.2018.07.012openalex-snapshot
Intensity-modulated radiotherapy with systemic chemotherapy improves survival in patients with nonmetastatic unresectable pancreatic adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
inferred← citeshttps://doi.org/10.1016/j.radonc.2021.09.001openalex-snapshot
Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2–3 studies
inferred← citeshttps://doi.org/10.1016/j.suc.2017.09.008openalex-snapshot
The Evolving Role of Radiation in Pancreatic Cancer
inferred← citeshttps://doi.org/10.1038/s41416-020-01120-zopenalex-snapshot
Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer
inferred← citeshttps://doi.org/10.1038/s41416-021-01416-8openalex-snapshot
Optimising treatment pathways for borderline and locally advanced pancreatic cancer: an adaptive personalised approach
inferred← citeshttps://doi.org/10.1038/s41575-018-0005-xopenalex-snapshot
Therapeutic developments in pancreatic cancer: current and future perspectives
inferred← citeshttps://doi.org/10.1038/s41575-023-00856-2openalex-snapshot
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer
inferred← citeshttps://doi.org/10.1038/s41598-021-86099-0openalex-snapshot
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer
inferred← citeshttps://doi.org/10.1055/a-1771-6811openalex-snapshot
S3-Leitlinie zum exokrinen Pankreaskarzinom – Kurzversion 2.0 – Dezember 2021, AWMF-Registernummer: 032/010OL
inferred← citeshttps://doi.org/10.1055/a-1856-7346openalex-snapshot
S3-Leitlinie zum exokrinen Pankreaskarzinom – Langversion 2.0 – Dezember 2021 – AWMF-Registernummer: 032/010OL
inferred← citeshttps://doi.org/10.1055/a-2338-3533openalex-snapshot
S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1
inferred← citeshttps://doi.org/10.1055/a-2338-3716openalex-snapshot
S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1
inferred← citeshttps://doi.org/10.1136/bmjopen-2021-050166openalex-snapshot
Treatment of unresectable locally advanced pancreatic cancer with percutaneous irreversible electroporation (IRE) following initial systemic chemotherapy (LAP-PIE) trial: study protocol for a feasibility randomised controlled trial
inferred← citeshttps://doi.org/10.1136/bmjopen-2022-068906openalex-snapshot
Evaluation of hypofractionated adaptive radiotherapy using the MR Linac in localised pancreatic cancer: protocol summary of the Emerald-Pancreas phase 1/expansion study located at Oxford University Hospital, UK
inferred← citeshttps://doi.org/10.1186/s12957-024-03587-zopenalex-snapshot
Prognostic efficacy of lymph node parameters in resected ampullary adenocarcinoma based on long-term follow-up data after adjuvant treatment
inferred← citeshttps://doi.org/10.1186/s13014-020-01712-2openalex-snapshot
Hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy for elderly patients with locally advanced pancreatic carcinoma
inferred← citeshttps://doi.org/10.1186/s13014-022-02001-wopenalex-snapshot
Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study
inferred← citeshttps://doi.org/10.1186/s40170-019-0202-2openalex-snapshot
Tissue of origin dictates GOT1 dependence and confers synthetic lethality to radiotherapy
inferred← citeshttps://doi.org/10.1200/op.22.00328openalex-snapshot
Pancreatic Adenocarcinoma Management
inferred← citeshttps://doi.org/10.1245/s10434-019-07261-7openalex-snapshot
Systematic Review of Surgical and Percutaneous Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Cancer
inferred← citeshttps://doi.org/10.1245/s10434-025-18664-0openalex-snapshot
Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cancer
inferred← citeshttps://doi.org/10.1245/s10434-026-19218-8openalex-snapshot
Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment
inferred← citeshttps://doi.org/10.1503/cmaj.201450openalex-snapshot
Advances in the management of pancreatic ductal adenocarcinoma
inferred← citeshttps://doi.org/10.1503/cmaj.201450-fopenalex-snapshot
Avancées dans la prise en charge de l’adénocarcinome canalaire pancréatique
inferred← citeshttps://doi.org/10.21037/cco-21-166openalex-snapshot
Current status and future perspective of neoadjuvant therapy in locally advanced and borderline resectable pancreatic adenocarcinoma: a narrative review
inferred← citeshttps://doi.org/10.21037/jgo-21-503openalex-snapshot
Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy
inferred← citeshttps://doi.org/10.21037/jgo.2018.02.02openalex-snapshot
Adjuvant radiation provides survival benefit for resected pancreatic adenocarcinomas of the tail
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1065586/v1openalex-snapshot
Factors Associated With Long-Term Survival in Gemcitabine-Concurrent Proton Radiotherapy For Non-Metastatic Locally Advanced Pancreatic Cancer: a Single-Center Retrospective Study
inferred← citeshttps://doi.org/10.22328/2079-5343-2025-16-2-20-28openalex-snapshot
Radiotherapy of pancreatic cancer patients. Past and present: a review
inferred← citeshttps://doi.org/10.2958/suizo.40.117openalex-snapshot
Conversion surgery in the era of multimodal treatment for pancreatic cancer
inferred← citeshttps://doi.org/10.3233/ch-190786openalex-snapshot
Clinical application of dynamic contrast enhanced ultrasound in monitoring the treatment response of chemoradiotherapy of pancreatic ductal adenocarcinoma
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1744566openalex-snapshot
MicroRNA-based strategies to overcome the immunotherapy barrier in pancreatic ductal adenocarcinoma
inferred← citeshttps://doi.org/10.3390/cancers15082213openalex-snapshot
Survival Outcomes and Failure Patterns in Patients with Inoperable Non-Metastatic Pancreatic Cancer Treated with Definitive Radiotherapy
inferred← citeshttps://doi.org/10.3390/cancers15133382openalex-snapshot
Radiotherapy in Pancreatic Cancer: To Whom, When, and How?
inferred← citeshttps://doi.org/10.3390/cancers15153771openalex-snapshot
Normo- or Hypo-Fractionated Photon or Proton Radiotherapy in the Management of Locally Advanced Unresectable Pancreatic Cancer: A Systematic Review
inferred← citeshttps://doi.org/10.3390/ijms20184543openalex-snapshot
Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions
inferred← citeshttps://doi.org/10.3390/jcm10081609openalex-snapshot
Irreversible Electroporation (IRE) in Locally Advanced Pancreatic Cancer: A Review of Current Clinical Outcomes, Mechanism of Action and Opportunities for Synergistic Therapy
inferred← citeshttps://doi.org/10.3390/jpm14070746openalex-snapshot
Novel Somay’s GLUCAR Index Efficiently Predicts Survival Outcomes in Locally Advanced Pancreas Cancer Patients Receiving Definitive Chemoradiotherapy: A Propensity-Score-Matched Cohort Analysis
inferred← citeshttps://doi.org/10.3892/ijo.2021.5290openalex-snapshot
Treatment optimization of locally advanced and metastatic pancreatic cancer (Review)
inferred← citeshttps://doi.org/10.5348/100077z04so2018oaopenalex-snapshot
Which patients with locally advanced pancreatic cancer treated with induction chemotherapy are most likely to benefit from post-induction chemoradiotherapy?
inferred← citeshttps://doi.org/10.7759/cureus.48106openalex-snapshot
Involved-Field Radiation Therapy for Patients With Unresectable Pancreatic Adenocarcinomas: Failure Pattern Analysis
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.